Wall Street analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to post earnings of ($0.30) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Sangamo Therapeutics’ earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.26). Sangamo Therapeutics posted earnings of ($0.18) per share during the same quarter last year, which suggests a negative year over year growth rate of 66.7%. The firm is scheduled to announce its next earnings results on Thursday, February 27th.
According to Zacks, analysts expect that Sangamo Therapeutics will report full-year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.41) to ($1.17). For the next fiscal year, analysts expect that the company will post earnings of ($1.18) per share, with EPS estimates ranging from ($1.75) to $0.10. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 27.32%. The firm had revenue of $21.96 million for the quarter, compared to the consensus estimate of $12.16 million. During the same quarter in the previous year, the company earned ($0.13) earnings per share. The business’s revenue was down 6.8% compared to the same quarter last year.
Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $229,000. Artal Group S.A. boosted its position in Sangamo Therapeutics by 1.3% during the 2nd quarter. Artal Group S.A. now owns 405,000 shares of the biopharmaceutical company’s stock worth $4,362,000 after acquiring an additional 5,000 shares during the last quarter. Wells Fargo & Company MN boosted its position in Sangamo Therapeutics by 25.1% during the 2nd quarter. Wells Fargo & Company MN now owns 821,420 shares of the biopharmaceutical company’s stock worth $8,847,000 after acquiring an additional 164,784 shares during the last quarter. Dupont Capital Management Corp acquired a new position in Sangamo Therapeutics during the 3rd quarter worth approximately $288,000. Finally, Virtus ETF Advisers LLC acquired a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $308,000. Institutional investors and hedge funds own 69.23% of the company’s stock.
SGMO traded up $0.51 during trading on Thursday, reaching $9.85. 1,237,000 shares of the company’s stock were exchanged, compared to its average volume of 1,811,887. The company has a market capitalization of $1.09 billion, a P/E ratio of -14.07 and a beta of 2.79. Sangamo Therapeutics has a fifty-two week low of $6.26 and a fifty-two week high of $13.91. The business has a 50 day moving average price of $9.03 and a 200 day moving average price of $10.37.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Recommended Story: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.